1 *Article*

2 3 4 Anti-diabetic Effects of Wild Soybean *Glycine Soja* Seed Extract on Type 2 Diabetic Mice and Human Hepatocytes induced Insulin Resistance

5 6 **Eunjung Son[1], Hye Jin Choi[2], Seung-Hyung Kim[2], Dong-Gyu Jang [3], Jimin Cha[4], Jeong June Choi[2*‡], Mee Ree Kim[5*‡], Dong-Seon Kim[1*‡]**

7 8 [1] Herbal Medicine Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Dajeon 34054, Republic of Korea; E.S.:ejson@kiom.re.kr, D-S.K:dskim@kiom.re.kr.

9 10 [2] Institute of Traditional Medicine and Bioscience, Daejeon University, Daejeon 300-716, Republic of Korea; H.J.C.:ejson@kiom.re.kr, S-H.K.:sksh518@dju.kr, J.J.C.: c27022@dju.ac.kr.

11 12 [3] Daejeon Bio Venturetown 306-7, Yuseong-daero 1662, Yuseong-gu, Daejeon 34054, Republic of Korea; D-G.J.: kocbio5267@hanmail.net.

13 14 [4] Department of Microbiology, Faculty of Natural Science, Dankook University, Cheonan, Chungnam 330-714, Republic of Korea; J.C.:jimincha@dankook.ac.kr.

15 16 [5] Department of Food and Nutrition, Chungnam National University, Yuseong-Gu, Dajeon, Republic of Korea; M.R.K.:mrkim@cnu.ac.kr .

17 18 ***** Correspondence: J.J.C: c27022@dju.ac.kr, Tel.: +82-42-280-2648; M.R.K: mrkim@cnu.ac.kr, Tel.: +82-42-821-6837; D-S.K: dskim@kiom.re.kr, Tel: +82-42-868-9639

19 ‡ Dong-Seon Kim, Mee Ree Kim, and Jeong June Choi contributed equally to this work

20 21 22 23 24 25 26 27 28 29 30 31 **Abstract:** Anti-diabetic effects of *Glycine soja* seed extract (GS) on Type 2 diabetes mellitus mouse model and human hepatocytes induced insulin resistance were investigated. 3 weeks old *db/db* mice were divided into 5 groups (*n* = 6) including two control groups and 3 GS treated groups with different doses. Oral administration of GS for 6 weeks to diabetic *db/db* mice reduced blood glucose level significantly in a dose dependent manner by 44.7% (300 mg/kg/day), 30.9% (150 mg/kg/day) and 21.1% (75 mg/kg/day). GS treatment also lowered significantly plasma level of HbA1c, insulin, IGF-1 and leptin, and increased that of adiponectin. GS treatment activated AMPK, and down-regulated GLUT2 in liver tissues of mice while up-regulated GLUT4 in muscle tissues of mice. In *in vitro* study with insulin resistance induced human hepatocyte, GS treatment increased glucose uptake and increased the activities of Akt and PPAR-γ in response to insulin. Treatment of GS appears to reduce blood glucose level by regulating energy metabolism positively through various metabolic pathways and reducing insulin resistance in Type 2 diabetes mellitus.

32 **Keywords:** *Glycine soja* seed; Type 2 diabetes mellitus; Antidiabetic; AMPK; Akt; PPAR-γ

33

34 1. Introduction

35 36 37 38 39 40 41 42 Many people suffer from a metabolic disorder, Type 2 Diabetes mellitus (T2DM) and its complications [1]. Insulin has a key role to maintain the blood glucose level within a narrow range. The main cause of T2DM has been reported to be insulin resistance though altered insulin secretion seems to be responsible to some extent [2]. IGF-1 has an almost 50% amino acid sequence homology with insulin and brings about nearly the same blood glucose lowering response [3]. It has been reported that the effect of IGF-1 on insulin sensitivity and its relation to T2DM [4, 5]. It has been reported that adiponectin [6] and leptin [7] concentrations in blood are functionally related to insulin resistance and T2DM.

43 44 Impaired energy metabolism often observed in T2DM, obesity, hyperlipidemia and cardiovascular diseases is closely related to biochemical malfunction in the cellular level [8]. Insulin resistance is

45　partly responsible for impaired energy metabolism that causes in turn various pathological events
46　[9]. AMPK acts as a sensor to maintain a balance of energy metabolism and has important biochemical
47　functions [10, 11]. AMPK stimulates or inhibits many downstream effectors in energy metabolism.
48　Thus, AMPK has been studied as a target for the development of drugs designed to correct impaired
49　energy metabolism since it has a key role in regulating both lipid and glucose metabolism [12, 13].

50　Akt pathway is a signal transduction pathway in response to extracellular signals and activated Akt
51　mediates many downstream responses by phosphorylating a range of intracellular proteins. In such
52　a way, Akt plays a key role in multiple cellular processes including glucose metabolism. Akt affects
53　glucose metabolism by increasing translocation of glucose transporters to the cell membrane,
54　stimulating glycogen synthesis by activation of the related enzymes [14].

55　Currently available hypoglycemic agents for T2DM have limitations to use because of side effects
56　and restrictions to treat the patients having kidney, liver, and heart problems [15-18]. Because PPAR-
57　γ regulates fatty acid storage and glucose metabolism, PPAR-γ agonists have been used in the
58　treatment of hyperglycemia as an insulin sensitizing agent [19]. PPAR-γ agonists also have side
59　effects [20], therefore, hypoglycemic agents increasing insulin sensitivity with less side effects still
60　need to be sought. It is desirable to find a safe herb from nature applicable for a long term treatment
61　to control hyperglycemia caused by T2DM.

62　*Glycine soja* is an annual winder plant widely grows in Korea, Japan, China, and Russia [21]. It is
63　known to be an original species of soybean (*Glycine max*). *Glycine soja* has been reported to have about
64　10% more protein and 10% less fat than soybean. *Glycine soja* has been reported to reduce blood
65　glucose and total cholesterol in normal rats [22]. However, anti-diabetic effects of *Glycine soja* on
66　T2DM and its relationship with energy metabolism and insulin resistance have not been reported yet.

67　**2. Results**

68　*2.1. Flavonoids and pinitol contents of GS*

69　Three flavonoids, epicatechin, daidzin, and genistin were identified in the sample of *Glycine soja* seed
70　extract. The extract sample contained 41.2 ± 0.1 mg/g epicatechin, 8.1 ± 0.3 mg/g daidzin, and 6.5 ± 0.1
71　mg/g genistin(Fig. 1(A)). The pinitol content of the sample was 1.21 ± 0.01 mg/g(Fig. 1(B)).

72

73

Figure 1. (A) Representative HPLC chromatogram of GS extract at 220 nm; 1) epicatechin, 2) daidzin, 3) genistin. (B) Representative total ion chromatogram of GS for pinitol quantification; 4) pinitol.

2.2. Animal study to evaluate effects of GS on T2DM

2.2.1. Effects of GS on weight change and FER

Weights of experimental mice were continuously gained during 6 weeks of treatment. No cases of weight loss were observed. As shown in Table 1, there are no significant differences in food intake, body weight gain and FER of *db/db* mice orally treated with 300 mg/kg/day (GS300), 150 mg/kg/day (GS150), and 75 mg/kg/day (GS75) of *Glycine soja* seed extract or 150 mg/kg/day of metformin (PC) for 6 weeks, compared to NC (negative control).

Table 1. Food intake, body weight gain, and food efficiency ratio of *db/db* mice treated with *Glycine soja* extract

Treatment	Food intake (g/day)	Body weight gain (g/day)	Food efficiency ratio (FER, %)
NC	6.32	0.753 ± 0.06	11.9 ± 1.00
PC	6.63	0.645 ± 0.03	9.73 ± 0.39

GS300	5.29	0.606 ± 0.03	11.4 ± 0.54
GS150	6.85	0.556 ± 0.05	8.11 ± 0.74
GS75	6.32	0.659 ± 0.04	10.4 ± 0.57

Oral doses of 300 mg/kg/day (GS300), 150 mg/kg/day (GS150), and 75 mg/kg/day (GS75) of *Glycine soja* extract or 150 mg/kg/day of metformin (PC) were administered for 6 weeks. Values are expressed as mean ± SEM (*n* = 6).

2.2.2. Effects of GS on plasma levels of AST, ALT, and BUN

To evaluate potential toxic effects of *Glycine soja* extract, plasma toxicity markers for liver (ALT, AST) and kidney (BUN) were assayed at the end of the experimental period. Plasma level of AST is shown to decrease significantly in PC compared to NC (Table 2). Plasma levels of AST and ALT are shown to decrease in GS groups compared to NC group as is shown in Table 2. However, the measurements were not statistically significant. Plasma level of BUN is not altered significantly in PC and GS groups compared to NC group. These data indicate that administration of 75 ~ 300 mg/kg/day of GS for 6 weeks has no significant adverse effects on experimental mice.

Table 2. Plasma levels of AST, ALT and BUN of *db/db* mice treated with *Glycine soja* extract

Treatment	AST (U/L)	ALT (U/L)	BUN (mg/dL)
NC	138.6 ± 30.5	77.6 ± 15.5	21.0 ± 3.3
GS300	101.1 ± 40.8	58.7 ± 12.7	22.2 ± 2.9
GS150	104.6 ± 22.2	66.3 ± 12.5	22.4 ± 4.4
GS75	122.0 ± 52.9	66.5 ± 9.7	25.9 ± 5.8
PC	92.4 ± 19.7*	57.0 ± 16.3	23.0 ± 2.1

Oral doses of 300 mg/kg/day (GS300), 150 mg/kg/day (GS150), and 75 mg/kg/day (GS75) of *Glycine soja* extract or 150 mg/kg/day of metformin (PC) were treated for 6 weeks. NC is a vehicle control. Values are expressed as mean ± SEM (n = 6). * $p < 0.05$ (compared to NC) express significant decrease as determined by one-way ANOVA.

2.2.3. Effects of GS on plasma lipid profile

The summary of plasma lipid profile is shown in Fig. 2. Plasma levels of triglyceride and LDL cholesterol are significantly decreased while HDL cholesterol level is significantly increased in PC group. LDL cholesterol level is significantly reduced in GS groups. However, triglyceride level is significantly reduced only in GS300 group.

Figure 2. Plasma levels of triglyceride, total cholesterol, HDL-cholesterol, and LDL-cholesterol of *db/db* mice treated with 300 mg/kg/day (GS300), 150 mg/kg/day (GS150), and 75 mg/kg/day (GS75) of *Glycine soja* extract, or 150 mg/kg/day of metformin (PC) for 6 weeks. Values are expressed as mean ± SEM (n = 6). * $p < 0.05$, ** $p < 0.01$, and **** $p < 0.001$ (compared to NC) express significant differences as determined by one-way ANOVA.

2.2.4. Effects of GS on blood level of glucose, HbA1c, insulin, IGF-1, adiponectin, and leptin

Blood glucose level of each experimental group was measured weekly from week 2 to week 6. Increment of blood glucose level is shown to decrease significantly from week 2 to week 6 in PC (increment of 118.2 mg/dL), GS300 (increment of 193.8 mg/dL), and GS150 (increment of 242.2 mg/dL), compared to NC (increment of 285.2 mg/dL) as shown in Fig. 3.

119

Figure 3. The blood glucose level of *db/db* mice treated with 300 mg/kg/day (GS300), 150 mg/kg/day (GS150), and 75 mg/kg/day (GS75) of *Glycine soja* extract, or 150 mg/kg/day of metformin (PC) for 6 weeks. Values are expressed as mean ± SEM (n = 6). ** $p < 0.01$, *** $p < 0.005$, and **** $p < 0.001$ (compared to NC) express significant decreases as determined by one-way ANOVA.

Blood glucose level measured after 6 weeks treatment is shown to decrease significantly in PC (225.2 ± 59.7 mg/dL), GS300 (331.3 ± 78.6 mg/dL), GS150 (414.3 ± 97.2 mg/dL), and GS75 (473.0 ± 21.4 mg/dL), compared to NC (599.3 ± 86.3 mg/dL) as shown in Fig. 4A. Plasma glucose level of GS groups is significantly decreased in a dose dependent manner.

Plasma HbA1c level is shown to decrease significantly in PC (3.8%) and GS300 (3.9%) compared to 8.2% in NC (Fig. 4B).

Plasma insulin level measured after 6 weeks treatment is shown to decrease significantly in PC (0.59 ± 0.28 ng/mL) and GS150 (1.59 ± 0.26 ng/mL), compared to NC (2.90 ± 0.33 ng/mL) as shown in Fig. 4C. Plasma IGF-1 level is significantly decreased in PC (110 ± 45 ng/mL), GS300 (174 ± 47 ng/mL), and GS150 (219.5 ± 28 ng/mL), compared to NC (380 ± 69 ng/mL) as shown in Fig. 3D. Plasma adiponectin level is significantly increased in PC (61.7 ± 8.3 μg/mL), GS300 (56.3 ± 7.8 μg/mL), and GS150 (71.2 ± 8.4 μg/mL), compared to NC (27.2 ± 8.2 μg/mL) as shown in Fig. 4E. Plasma leptin level is significantly decreased in PC (390.9 ± 76.4 ng/mL), GS300 (436.7 ± 39.6 ng/mL), and GS150 (448.4 ± 25.7 ng/mL), compared to NC (692.4 ± 148.2 ng/mL).

138

Figure 4. (A) Plasma glucose level, (B) plasma HbA1C level, (C) plasma insulin level, (D) plasma IGF-1 level, (E) plasma adiponectin level, and (F) plasma leptin level of *db/db* mice treated with 300 mg/kg/day (GS300), 150 mg/kg/day (GS150), and 75 mg/kg/day (GS75) of *Glycine soja* extract, or 150 mg/kg/day of metformin (PC) for 6 weeks. Values are expressed as mean ± SEM (n = 6). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$, and **** $p < 0.001$ significant decreases as determined by one-way ANOVA.

144

2.2.5. Effects of GS on expression of AMPK, GLUT-2, and GLUT-4

AMPK expression is significantly increased in liver tissues of PC and GS300, compared to NC as shown in Fig. 5A. GLUT-2 expression is significantly decreased in liver tissues of PC, GS300, and GS150, compared to NC as shown in Fig. 5B. GLUT-4 expression is significantly increased in muscle tissues of GS300 and GS150, compared to NC as shown in Fig. 5C.

150

Figure 5. (A) p-AMPK expression in liver tissue, (B) GLUT-2 expression in liver tissue, and (C) GLUT-4 expression in muscle tissue of *db/db* mice treated with 300 mg/kg/day (GS300), 150 mg/kg/day (GS150), and 75 mg/kg/day (GS75) of *Glycine soja* extract, or 150 mg/kg/day of metformin (PC) for 6 weeks. Values are expressed as mean ± SEM (n = 6). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$, and **** $p < 0.001$ (compared to NC) express significant increase as determined by one-way ANOVA.

156

157   2.2.6. Histological observations

158   Histological observation reveals (Fig. 6) that lipid droplets are less accumulated and smaller in size
159   in liver tissues of PC and GS300, compared to NC. Fig. 6 shows that the size of adipocytes is smaller
160   in subcutaneous fat tissues of PC and GS300, compared to NC.

Figure 6. Stained tissues of liver and subcutaneous fat of *db/db* mice treated with 300 mg/kg/day (GS300), 150 mg/kg/day (GS150), and 75 mg/kg/day (GS75) of *Glycine soja* extract, or 150 mg/kg/day (PC) of metformin for 6 weeks.

2.3. In vitro study to evaluate effects of GS on T2DM

2.3.1. Effects of GS on glucose uptake, Akt activity, and PPAR-γ activity in hepatocytes

Human HepG2 cell line was used to evaluate the anti-diabetic effects of GS on glucose uptake by hepatocytes. The concentration level for GS treatment was validated by MTT assay that demonstrated no cytotoxicity throughout all the concentrations applied for the experiments (Fig. 7A). GS treatment significantly increased glucose uptake by HepG2 cells approximately 60% at the concentrations of 0.1, 1, and 10 µg/mL (Fig. 7B). The level of glucose uptake was determined by measuring intracellular level of 2-deoxyglucose.

The effects of GS on insulin responsiveness were investigated. It is known that the responsiveness to insulin signaling with respect to Akt activity is decreased in T2DM [23]. To mimic T2DM in this experiment, palmitate was treated to reduce insulin sensitivity, leading to the suppression of insulin-induced Akt phosphorylation. In Fig. 6C, GS treatments show significant recovery effects against the attenuated Akt phosphorylation caused by palmitate.

As shown in Fig. 6D, palmitate treatment attenuates insulin-induced transcriptional activity of PPAR-γ whilst GS treatment (10 µg/mL) significantly recovers from the attenuated transcriptional activity of PPAR-γ.

Figure 7. (A) Cytotoxicity test for GS treatment to HepG2 cells. (B) Effects of GS on glucose uptake in HepG2 cells. **$p < 0.01$, ***$p < 0.001$ vs. Con. 2-DG; 2-deoxyglucose, Con; control, Ins; insulin, GS; *Glycine soja* extract. (C) Effects of GS on insulin-induced Akt signaling pathway in HepG2 cells. †††$p < 0.001$ vs. Nor; *$p < 0.05$, **$p < 0.01$ vs. Ins + Pal. Nor; no treatment, Ins; insulin only, Ins + Pal; insulin with palmitate, GS; *Glycine soja* extract with palmitate and insulin. (D) Effects of GS on PPAR-γ activity in HepG2 cells. †††$p < 0.001$ vs. control, ‡‡‡ $p < 0.001$ vs. insulin only, ***$p < 0.001$ vs. insulin with palmitate, GS; *Glycine soja* extract.

3. Discussion

This study was designed to evaluate anti-diabetic effects of GS on T2DM animal model of *db/db* (BKS.Cg-m+/+Lepr^db^/J) mice. During the weeks study, treatment of GS showed no significant adverse effects on the liver and kidney of experimental mice. Administration of GS is regarded to be safe considering observations on food intake, body weight gain and behavior of experimental mice.

T2DM is due to insulin resistance and inadequate insulin production by β-cells, though the causes are not completely understood so far. Two distinctive pathways are important in the regulation of blood glucose level. One is AMPK dependent mechanisms, and the other is insulin-dependent pathway that upregulates serine/threonine protein kinase Akt [23]. Metformin, used to treat T2DM by AMPK, increases peripheral glucose intake while reducing glucose production by liver. [24]. Akt signaling plays a key role in insulin-stimulated glucose uptake by both skeletal muscle and adipose tissue while inhibiting the release of hepatic glucose [25]. Insulin activates Akt phosphorylation which in turn promotes GLUT-4 translocation and glucose uptake in skeletal muscle [26]. In T2DM, the responsiveness to insulin signaling with respect to Akt activity is decreased [27].

In T2DM, hyperinsulinemia increases blood level of IGF-1 [28]. In this study, GS treatment reduced blood levels of glucose and HbA1c in T2DM animal model. However, GS treatment also reduced blood levels of insulin and IGF-1. This outcome seems to be achieved by increasing insulin (and IGF-1) responsiveness against insulin resistance of T2DM. Activation of AMPK by GS treatment is believed to assist sensitizing insulin considering that activated AMPK, in turn, inhibits GLUT-2 expression in liver and activates GLUT-4 expression in muscle as demonstrated in this study.

Though glucose disposal occurs only a small fraction by adipose tissue, physiological role of adipose tissue is crucial in regulating glucose metabolism [29]. Leptin is an adipokine mostly produced by adipocytes. Blood glucose level is regulated by leptin as well as by insulin. Leptin has

213 positive effects on energy metabolism resulting in weakening of hyperglycemia, hyperinsulinemia,
214 and insulin resistance [30]. Adiponectin is known to modulate a number of metabolic processes,
215 including glucose regulation and fatty acid oxidation [31]. Adiponectin has also been reported to
216 mediate insulin-sensitizing effect to improve hyperglycemic conditions and hyperinsulinemia [32]. It
217 has been reported that the reduction of adiponectin is associated with insulin resistance [33].
218 Physiological relationship between adipokines released from adipocytes and activation of AMPK has
219 been reported [34].

220   In our study, blood level of adiponectin was increased while that of leptin was decreased by GS
221 treatment. This outcome suggests that GS treatment increases leptin sensitivity as well as insulin
222 sensitivity. And elevated adiponectin seems to regulate energy metabolism positively to improve
223 hyperglycemic conditions, possibly via insulin-sensitizing effect.

224   Our *in vitro* study demonstrated that GS treatment increased glucose uptake by hepatocytes. GS
225 treatment also activated Akt acting as a key effector of insulin signaling pathway in an induced
226 insulin resistance model, and recovered from the attenuated insulin-induced transcriptional activity
227 of PPAR-γ. This outcome supports the evidences of our animal study that GS treatment works
228 positively on energy metabolism regulating blood glucose level and on insulin sensitivity.

229   Treatment of GS is thought to have effects on regulating energy metabolism to reduce blood
230 glucose level and increasing sensitivities of insulin, IGF-1, and leptin, and activating AMPK and Akt
231 in T2DM.

4. Materials and Methods

4.1. Preparation of wild Glycine soja seed extract

234 The seeds of wild *Glycine soja* were collected in Moonkyung, Korea. After ten days of natural dry, the
235 seeds were pulverized to powder. To make GS extract sample, 1 kg of the powder was extracted with
236 10 L of water at 80℃ for 4 hrs. The extracts were filtered, and then concentrated under reduced
237 pressure in a rotary evaporator. Water extract sample was prepared by lyophilization of the extract.

4.2. Quantitative analysis of extract samples for flavonoids and pinitol

239 Flavonoids in samples were analyzed by reverse phase-high performance liquid chromatography of
240 Waters Alliance 2695 system (Waters Co., Milford, MA, USA) coupled with 2996 photodiode array
241 detector. Acquity UPLC® BEH C18 column (2.1 × 100 mm, 1.7 μm; Waters, Milford, MA, USA) was
242 used for the stationary phase. The mobile phase was composed of 0.1% (*v/v*) formic acid in water (A)
243 and 0.1% (*v/v*) formic acid in acetonitrile (B). At zero time, the mobile phase consisted of 95% A and
244 5% B and was held for 20 min. From 20 to 25 min, a gradient was applied to 65% A and 35% B, and
245 from 25 to 27 min, to 0% A and 100% B, then after 27 min, to 95% A and 10% B. For separation, 0.4
246 mL/min of flow rate and 2 μL of injection volume were kept throughout analyses that performed at
247 40℃.

248 Pinitol in samples was analysed by reverse phase-high performance liquid chromatography of
249 Waters Alliance 2695 system (Waters Co., Milford, MA, USA) coupled with 2996 photodiode array
250 detector. Acquity UPLC® HSS T3 column (2.1 × 100 mm, 1.8 μm; Waters, Milford, MA, USA) was
251 used for the stationary phase. The mobile phase was composed of 0.1% (*v/v*) ammonium hydroxide
252 in water (A) and acetonitrile (B). At zero time, the mobile phase consisted of 98% A and 2% B and
253 was held for 10 min. From 10 to 12 min, a gradient was applied to 30% A and 70% B, and from 12 to
254 13 min, to 98% A and 2% B, then after 13 min, to 98% A and 2% B. For separation, 0.5 mL/min of flow
255 rate and 5 μL of injection volume were kept throughout analyses that performed at 40oC. Positive
256 electrospray ionization mode (ESI+) was used for the detection and pinitol (m/z 194.2) ion was
257 monitored in the single ion-monitoring (SIM) mode. The following MS conditions were applied. The
258 capillary voltage and probe temperature were set to 0.8 kV and 600℃, respectively. And nitrogen
259 was used as dissolving and nebulizer gas. The cone voltage was set to 5 V.

260 Identification of flavonoids was made by comparing retention times and UV spectra for the peaks of
261 HPLC/PDA chromatogram to those of commercially available standards. Quantification of sample
262 flavonoids was made in comparison to the mixture of external standards of known concentration.
263 Peak area of chromatograms was determined at 220 nm. Identification of pinitol was made by
264 comparing retention times and mass spectra for the peaks of HPLC/QDa TIC with those of reference
265 standard (Sigma, St. Louis, MO, USA). Quantification of sample pinitol was made in comparison to
266 the external standard with selected ion chromatography mode.

267 *4.3. Animal study to evaluate effects of GS on T2DM*

268 4.3.1. Animals and experimental treatments

269 3 weeks old *db/db* (BKS.Cg-*m+/+Lepr^db^/J*) mice (19 ~ 22 g) were purchased from Daehan Biolink
270 Co., Eumsung, Korea and allowed to adapt for one week. The mice were housed in an air-conditioned
271 SPF animal room having a 12 h light/12 h dark cycle at $23 \pm 1°C$ temperature and $45 \pm 11\%$ humidity.
272 The committee for animal welfare at Daejeon University approved the experimental protocols used
273 in this study(DJUARB2011-005). All animal procedures were conducted in accordance with the Guide
274 for the Care and Use of Laboratory Animals (NIH publication number 85–23, 1996 edition).
275 They were allowed to access to diet and water ad libitum. Mice were divided into 5 groups of
276 NC (negative control), PC (positive control), and 3 GS (*Glycine soja* seed extract treatment) groups of
277 different doses. 6 mice were allocated to each group. NC group was administered orally with saline
278 while PC group was administered with 150 mg/kg/day of metformin, a well-known drug being used
279 widely to treat T2DM. 75 mg/kg/day (GS75), 150 mg/kg/day (GS150) and 300 mg/kg/day (GS300) of
280 oral dosage were applied for GS groups. Oral administration to mice was made twice a day by
281 dissolving a half of daily dosage in 0.2 mL of saline. The experiment was lasted for 6 weeks.

282 4.3.2. Measurement of weight change and food efficiency ratio (FER)

283 Body weight gain and amount of food intake were measured at the same time and the same day of a
284 week during 6 weeks of experimental period after a week of adaptation period. Average body weight
285 gain and average amount of food intake were calculated daily and recorded. FER was calculated by
286 (total weight gain / total food intake) × 100.

287 4.3.3. Measurement of blood glucose level

288 Blood glucose level of mice was measured weekly. The mice were fasted for 6 hrs before collecting
289 blood samples from the tail. The collected blood was immediately transferred to a portable kit (One
290 TOUCH@Ultra, Johnson & Johnson, New Brunswick, NJ, USA) to measure the blood glucose level.

291 4.3.4. Plasma assays for biochemical parameters

292 At the end of 6 week experimental period, the mice were fasted for 16 hrs prior to sacrifice. Blood
293 samples were collected from the tail and transferred to ethylene diamine tetra acetic acid vacuum
294 tube and stirred to prevent blood clotting. They were then centrifuged at 3000 rpm for 15 min at 4 ℃.
295 The supernatants were collected and the separated plasma samples were stored at -80 ℃. The plasma
296 level of triglyceride, total cholesterol, high density lipoprotein (HDL) cholesterol, low density
297 lipoprotein (LDL) cholesterol, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
298 was analyzed by automatic biochemical analyzer (Hitachi-720, Hitachi Medical, Japan). The plasma
299 concentration of HbA1C (Crystal Chem, IL, USA), insulin (Shibayagi, Shibukawa, Japan), IGF-1
300 (Insulin-like growth factor-1; R&D system, MN, USA), adiponectin (R&D system, MN, USA), and
301 leptin (R&D system, MN, USA) were assayed with corresponding mouse ELISA (enzyme-linked
302 immunosorbent assay) kits according to the protocols offered by the manufacturers. Plasma
303 concentrations of the biomarkers were calculated by measuring absorbance with a microplate reader
304 (Labsystems, Vantaa, Finland).

305 4.3.5. Assay for p-AMPK, GLUT-2, and GLUT-4 expressions

306   Tissue samples of mouse liver and muscle were added with PBS containing protease inhibitor and
307   homogenized, and then centrifuged at 10,000 g for 5 min. Protein concentration was determined by
308   BCA assay (Pro-measure, Intron Biotechnology, Seoul, Republic of Korea). Quantified proteins were
309   separated by 12% SDS-polyacrylamide gel (Bio-Rad, CA, USA) electrophoresis and transferred onto
310   PVDF membrane (Bio-Rad, CA, USA). The membranes were blocked with 5% skimmed milk and
311   then incubated at 4 ℃ overnight with primary antibodies (Cell Signaling Technology, MA, USA)
312   against AMPK, p-AMPK, β-actin, GLUT-2, and GLUT-4. The membranes were then incubated with
313   the corresponding horseradish peroxidase-conjugated secondary antibodies (Santa Cruz
314   Biotechnology, TX, USA) for 1 hr at room temperature. Antibody binding was visualized by
315   chemiluminescence detection system (Amersham Bioscience, NJ, USA) and image analyzer (LAS-
316   3000, Fujifilm, Tokyo, Japan). Quantification of the expressed proteins was estimated with ImageJ
317   software (NIH, MD, USA).

318   4.3.6. Histological observations

319   After sacrificing mice, the tissues of liver and subcutaneous fat were fixed in 10% neutral formalin
320   solution for one day and embedded in paraffin. All tissues were sliced to 10 μm in thickness and
321   stained with H&E (hematoxylin and eosin). Histological examination was performed with the stained
322   samples and photos were taken with light microscope (Olympus BX51, Olympus Optical Co., Japan).
323   The differentiated cells were washed twice with PBS and then fixed with 10% formalin for 1 hr. The
324   fixed cells were stained with 0.3% oil red O solution for 10 min. The cells were visualized with
325   Olympus CKX41 microscope (Olympus, Tokyo, Japan) and photographed at 100× magnification
326   using the Motic image Plus 2.0 program (Motic, Causeway Bay, Hong Kong).

327   *4.4. In vitro experiments to evaluate effects of GS on T2DM*

328   4.4.1. Cell culture

329   Human hepatocyte, HepG2 cell line was purchased from Korea cell line Bank (Seoul, Korea). The
330   cells were cultured in Dulbecco's modified eagle's medium (DMEM; Lonza, Walkersville, MD, USA)
331   with 10% fetal bovine serum (FBS; Lonza), 100 U/mL penicillin and 100 µg/mL streptomycin (Lonza)
332   in a humidified incubator at 37 ℃.

333   4.4.2. MTT assay

334   HepG2 cells were seeded in a 96-well plate at the concentration of 2 × 10^5 cells/mL and treated with
335   GS at the concentrations from 0.1 to 100 µg/mL for 24 hrs. After then, the cells were washed with PBS
336   and incubated with MTT solution (5 mg/mL) for 4 h at 37 ℃. The crystal formazan was dissolved in
337   dimethyl sulfoxide. The optical density was measured by microplate reader at 570 nm microwave
338   length.

339   4.4.3. Glucose uptake assay

340   Glucose uptake assay was performed with Glucose Uptake Assay kit (Abcam) according to
341   manufacturer's instruction. Briefly, HepG2 cells were seeded in a 96-well plate at the concentration
342   of 2 × 10^5 cells/mL, and treated with GS (0.1, 1 and 10 µg/mL) for 24 hrs. After then, the cells were
343   incubated with BSA-KRPH (Krebs ringer phosphate HEPES) for 40 min and treated with insulin (10
344   µg/mL) or GS (0.1, 1 and 10 µg/mL) for 20 min. The cells were, then, treated with 2-deoxyglucose (10
345   mM) for 20 min and washed with PBS. The optical density was measured by microplate reader at 405
346   nm.

347   4.4.4. Akt activity assay

348   HepG2 cells were seeded in a 96-well plate at the concentration of 2 × 10^5 cells/mL. The cells were
349   pre-treated with GS for 1 hr prior to incubation in a cell culture media containing BSA-palmitate for
350   24 hrs. Then, the cells were incubated with insulin (10 µg/mL) for 20 min. The cell lysates were

351 harvested to measure Akt activity by Phospho-Akt ELISA kit (R&D systems, Minneapolis, MN, USA)
352 according to manufacturer's manual.

353 4.4.5. PPAR-γ activity assay

354 HepG2 cells were seeded on 60-mm culture dishes at the concentration of 2×10^5 cells/mL. The cells
355 were pre-treated with GS for 1 hr prior to incubation in a cell culture media containing BSA-palmitate
356 in the presence or absence of GS for 24 hrs. After then, the cells were treated with insulin (10 μg/mL)
357 for 20 min before the cell nuclear extracts were harvested by nuclear extract kit (Active Motif,
358 Carlsbad, CA, USA). The transcriptional activity of PPAR-γ was measured by TransAM PPAR-γ
359 Transcription Factor Assay kit (Active Motif, California, USA) according to manufacturer's protocol.

360 *4.5. Statistical analysis*

361 Differences between groups were assessed by an analysis of variance (one way ANOVA) followed
362 by Tukey's test for verification (GraphPad Prism 7.0, GraphPad software Inc., San Diego, USA). The
363 data are presented as mean ± SEM (Standard Error of the Mean) or mean ± SD (Standard Deviation).
364 Differences were considered significant when the p values were less than 0.05.
365

5. Conclusions

367 Oral administration of GS at the doses of 300 mg/kg/day and 150 mg/kg/day showed significant anti-
368 diabetic effects on T2DM. However, administration of GS at the dose of 75 mg/kg/day fell into non-
369 efficacious dosage region. During the 6 week mice study, GS treatments showed no significant
370 adverse effects to experimental mice.

371 Treatment of *Glycine soja* seed extract appears to reduce blood glucose level by regulating energy
372 metabolism positively through various metabolic pathways and reducing insulin resistance in T2DM.

373 With an appropriate standardization, GS can be developed as a hypoglycemic agent increasing
374 insulin sensitivity having no adverse effects for a long term treatment of T2DM.
375

376 **Author Contributions:** Conceptualization; D-S.K., M.R.K; Formal analysis, E.S., H.J.C., S-H.K, D-G. J.;
377 Writing-Original Preparation, E.S., J.J.C.; Writing-Review & Editing, J.C., J.J.C.; All author read and approved
378 the final manuscript.

383 **Conflicts of Interest:** The authors declare no conflict of interest.
384

References

386
387 1. Akash, M.S.H.; K. Rehman; S.Q. Chen. Role of inflammatory mechanisms in pathogenesis of type 2
388   diabetes mellitus. *Journal of Cellular Biochemistry* **2013,** 114(3), 525-531.
389 2. Collaboration, N.C.D.R.F. Worldwide trends in diabetes since 1980: a pooled analysis of 751
390   population-based studies with 4.4 million participants. *Lancet* **2016**, 387(10027), 1513-1530.
391 3. Boulware, S.D.; Tamborlane, W.V.; Rennert, N.J.; Gesundheit, N.; Sherwin, R.S. Comparison of the
392   metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response
393   relationships in healthy young and middle-aged adults. *J Clin Invest* **1994**, 93(3), 1131-1139.

4. Sandhu, M.S.; Heald, A.H.; Gibson J.M.; Cruickshank, J.K.; David, D.B.; Wareham, N.J. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. *Lancet* **2002,** 359(9319), 1740-1745.

5. Schneider, H.J.; Friedrich, N.; Klotsche, J.; Schipf, S.; Nauck, M.; Völzke, H.; Sievers, C.; Pieper, L.; März, W.; Wittchen H.; Stalla, G. K.; Wallaschofski, H. Prediction of incident diabetes mellitus by baseline IGF1 levels. *Eur J Endocrinol* **2011**, 164(2), 223-229.

6. Sheng, T.; K. Yang. Adiponectin and its association with insulin resistance and type 2 diabetes. *J Genet Genomics* **2008,** 35(6), 321-326.

7. Fischer, S.; Hanefeld, M.; Haffner, S.M.; Fusch, C.; Schwaneveck, U.; Köhler, C.; Fücker, K.; Julius, U. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. *Acta Diabetol* **2002,** 39(3), 105-110.

8. Wing, R.R.; Goldstein, M.G.; Acton, K.J.; Birch, L.L.; Jakicic, J.M.; Sallis Jr, J.F.; Smith-West, D.; Jeffery, R.W.; Surwit, R.S. Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. *Diabetes Care* **2001,** 24(1), 117-123.

9. Chang, L.; Chiang, S.H.; Saltiel, A.R. Insulin signaling and the regulation of glucose transport. *Molecular Medicine* **2004,** 10(7-12), 65-71.

10. Zhang, B.B.; Zhou, G.C.; Li, C. AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome. *Cell Metabolism* **2009**, 9(5), p. 407-416.

11. Evans, A.M.; Mustard, K. J.W.; Wyatt, C.N.W.; Peers, C.; Dipp, M.; Kumar, P.; Kinnear, N.P.; Hardie, D.G. Does AMP-activated protein kinase couple inhibition of mitochondrial oxidative phosphorylation by hypoxia to calcium signaling in O-2-sensing cells? *Journal of Biological Chemistry* **2005,** 280(50), 41504-41511.

12. Kahn, B.B.; Alquier, T.; Carling, D.; Hardie, D.G. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metabolism* **2005,** 1(1), 15-25.

13. Wong, A.K.F.; Howie, J.H.; Petrie, J.R.; Lang, C.C. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. *Clinical Science* **2009**. 116(7-8), 607-620.

14. Nicholson, K.M.; Anderson, N.G. The protein kinase B/Akt signalling pathway in human malignancy. *Cellular Signalling* **2002**, 14(5), 381-395.

15. Katsuki, A.; Sumida, Y.; Urakawa, H.; Gabazza, E.C.; Murashima, S.; Maruyama, N.; Morioka, K.; Nakatani, K.; Yano, Y.; Adachi, Y. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. *Diabetes Care* **2003**, 26(8), 2341-2344.

16. Rains, S.G.; Wilson, G.A.; Richmond, W.; Elkeles, R. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. *Diabet Med* **1988,** 5(7), 653-658.

17. Zhou, G., Li, R.M.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M.F.; Goodyear, L.J.; Moller, D.E. Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest* **2001,** 108(8), 1167-1174.

18. Altun, E.; Kaya, B.; Paydaş, S.; Sarıakçalı, B.; Karayaylalı, I. Lactic acidosis induced by metformin in a chronic hemodialysis patient with diabetes mellitus type 2. *Hemodial Int* **2014**, 18(2), 529-531.

19. Li, Y.; Qi, Y.; Huang, T.H. W.; Yamahara, J.; Roufogalis, B.D. Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties. *Diabetes Obesity & Metabolism* **2008**, 10(1), 10-17.

20. Atanasov, A.G.; Wang, J.N.; Gu, S.P.; Bu, J.; Kramer, M.P.; Baumgartner, L.; Fakhrudin, N.; Ladurner, A.; Malainer, C.; Vuorinen, A.; Noha, M.M.; Schwaiger, S.; Rollinger, J.M.; Schuster, D.; Stuppner, H.; Dirsch, V.M.; Heiss, E.H. Honokiol: A non-adipogenic PPAR gamma agonist from nature. *Biochimica Et Biophysica Acta-General Subjects* **2013**, 1830(10), 4813-4819.

21. Chung, G.; Singh, R.J. Broadening the genetic base of soybean: A multidisciplinary approach. *Critical Reviews in Plant Sciences* **2008**, 27(5), 295-341.

22. Kim, M.; Kim, D.K.; Cha, Y.S. Black Adzuki Bean (*Vigna angularis*) Extract Protects Pancreatic Cells and Improves Glucose Tolerance in C57BL/6J Mice Fed a High-Fat Diet. *Journal of Medicinal Food* **2016**. 19(5), 442-449.

23. Mackenzie, R.W.; Elliott, B.T. Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. *Diabetes Metab Syndr Obes* **2014,** 7, 55-64.

24. Lalau, J.D.; Race, J.M. Metformin and lactic acidosis in diabetic humans. *Diabetes Obes Metab* **2000**, 2(3), 131-137.

449 25. Scott, J.W.; Norman, D.G.; Hawley, S.A.; Kontogiannis, L.; Hardie, D.G. Protein kinase substrate
450   recognition studied using the recombinant catalytic domain of AMP-activated protein kinase and a
451   model substrate. *J Mol Biol* **2002**, 317(2), 309-323.
452 26. Sakamoto, K.; Holman, G.D. Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of
453   GLUT4 traffic. *Am J Physiol Endocrinol Metab* **2008**, 295(1), E29-37.
454 27. Wolfrum, S.; Dendorfer, A.; Schutt, M.; Weidtmann, B.; Heep, A.; Tempel, K.; Klein, H.H.; Dominiak,
455   P.; Richardt, G. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the
456   phosphatidylinositide 3-kinase/Akt pathway. *J Cardiovasc Pharmacol* **2004**, 44(3), 348-355.
457 28. de Herder, W.W.; Eng, C. Obesity, diabetes mellitus, and cancer. *Endocr Relat Cancer* **2012**, 19(5), E5-7.
458 29. Chang, L.; Chiang, S.H.; Saltiel, A.R. Insulin signaling and the regulation of glucose transport. *Mol*
459   *Med*, **2004**, 10(7-12), 65-71.
460 30. Paz-Filho, G.; Mastronardi, C.; Wong, M.; Licinio, J. Leptin therapy, insulin sensitivity, and glucose
461   homeostasis. *Indian J Endocrinol Metab* **2012**, 16(3), S549-555.
462 31. Diez, J.J.; Iglesias, P. The role of the novel adipocyte-derived hormone adiponectin in human disease.
463   *Eur J Endocrinol* **2003,** 148(3), 293-300.
464 32. Ukkola, O.; Santaniemi, M. Adiponectin: a link between excess adiposity and associated
465   comorbidities? *Journal of Molecular Medicine-Jmm* **2002**, 80(11), 696-702.
466 33. Yadav, A.; Kataria M.A.; Saini, V.; Yadav, A. Role of leptin and adiponectin in insulin resistance. *Clinica*
467   *Chimica Acta* **2013,** 417, 80-84.
468 34. Banerjee, R.R.; Rangwala, S.M.; Shapiro, J.S.; Rich, A.S.; Rhoades, B.; Qi, Y.; Wang, J.; Rajala, M.W.;
469   Pocai, A.; Scherer, P.E.; Steppan, C.M.; Ahima, R.S.; Obici, S.; Rossetti, L.; Lazar, M.A. Regulation of
470   fasted blood glucose by resistin. *Science* **2004,** 303(5661), 1195-1198.
471
472